Hui-Yin Li

USPTO Granted Patents = 34 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 14)

Average Co-Inventor Count = 3.2

ph-index = 14

Forward Citations = 800(Granted Patents)

Location History:

Newark, DE (US) (1996 - 2002)
Hockessin, DE (2014)
Hockessin, DE (US) (2001 - 2022)
Hockessen, DE (US) (2022)

Company Filing History:

Bristol-myers Squibb Pharma Company

patents

5 out of 147

Incyte Holdings Corporation

patents

4. 5 out of 106

Dupont Pharmaceuticals Company

patents

5. 3 out of 3,681

Bristol-myers Squibb Compnay

patents

6. 2 out of 206

The Dupont Merck Pharmaceutical Company

patents

7. 1 out of 290

Enanta Pharmaceuticals, Inc.

Asana Biosciences, LLC

patents

10. 1 out of 8

Actimis Pharmaceuticals, Inc.

patents

11. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2022

Loading Chart...

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11414427 - Solid forms of stemospironine and its salts (2022-08-16),

2. 11213528 - Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2022-01-04),

3. 10610530 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2020-04-07),

4. 10125150 - Crystalline forms of a PI3K inhibitor (2018-11-13),

5. 10016429 - Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2018-07-10),

6. 9988401 - Crystalline forms of a PI3K inhibitor (2018-06-05),

7. 9505719 - Synthesis and use of kinase inhibitors (2016-11-29),

8. 9464088 - Piperidin-4-yl azetidine derivatives as JAK1 inhibitors (2016-10-11),

9. 9376439 - Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2016-06-28),

10. 9126991 - Radezolid salts and polymorphic forms thereof (2015-09-08),

11. 8865741 - Aminoindane compounds and use thereof in treating pain (2014-10-21),

12. 8829013 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2014-09-09),

13. 8822481 - Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2014-09-02),

14. 8765734 - Piperidin-4-yl azetidine derivatives as JAK1 inhibitors (2014-07-01),

15. 8722693 - Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (2014-05-13),

Hello! I'm glad that you're interested in learning about the inventor Hui-Yin Li from Hockessin, DE (US) and his remarkable contributions to the field of innovations and inventions.

Title: The Inventive Journey of Hui-Yin Li: Pioneering Advances in Pharmaceutical Sciences

Introduction:

Hui-Yin Li, a visionary inventor hailing from Hockessin, DE (US), has left a profound impact in the realm of pharmaceutical sciences, boasting an impressive portfolio of 34 patents that exemplify his ingenuity and dedication to innovation.

Latest Patents:

His latest patents showcase his expertise in developing groundbreaking pharmaceutical compounds, such as the solid forms of stemospironine and its salts, which have immense therapeutic potential in the treatment of various medical conditions. Additionally, the salts of the janus kinase inhibitor highlight his commitment to advancing research in the field of pharmacology.

Career Highlights:

Having worked with renowned companies like Incyte Corporation and Bristol-Myers Squibb Pharma Company, Hui-Yin Li has garnered rich experience and insights that have undoubtedly influenced his inventive pursuits. His explorations into novel pharmaceutical formulations have paved the way for cutting-edge treatments in the healthcare industry.

Collaborations:

Throughout his illustrious career, Hui-Yin Li has collaborated with esteemed professionals in the field, including Pasquale N Confalone and Philip Ma, fostering a culture of innovation and knowledge-sharing that has fueled his creative endeavors.

Conclusion:

In conclusion, Hui-Yin Li stands as a pioneering figure in the domain of pharmaceutical innovations, with a prolific patent portfolio that underscores his unwavering commitment to advancing healthcare solutions. His inventive spirit and collaborative approach have undoubtedly shaped the landscape of modern medicine, leaving a lasting legacy in the field of inventions and discoveries.

This text is generated by artificial intelligence and may not be accurate.